Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL

被引：14

作者：

Wierda, W ^{[1
]}

Faderl, S ^{[1
]}

O'Brien, S ^{[1
]}

Cortes, J ^{[1
]}

Ferrajoli, A ^{[1
]}

Giles, F ^{[1
]}

Andreff, M ^{[1
]}

Koller, C ^{[1
]}

Kantarjian, H ^{[1
]}

Keating, M ^{[1
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2004年 / 104卷 / 11期

关键词：

D O I：

10.1182/blood.V104.11.340.340

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

340

引用

页码：101A / 101A

页数：1

共 50 条

[1] Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL.
Wierda, W
O'Brien, S
Ferrajoli, A
Faderl, S
Kornblau, SM
Andreef, M
Koller, C
Garcia-Manero, G
Thomas, D
Kantarjian, H
Keating, M
BLOOD, 2003, 102 (11) : 360B - 360B
[2] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL.
Wierda, William G.
O'Brien, Susan
Faderl, Stefan
Ferrajoli, Alessandra
Ravandi-Kashani, Farhad
Cortes, Jorge
Giles, Francis
Andreeff, Michael
Koller, Charles Asa
Lerner, Susan
Kantarjian, Hagop M.
Keating, Michael J.
BLOOD, 2006, 108 (11) : 14A - 14A
[3] Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL
Wierda, William G.
O'Brien, S.
Ferrajoli, A.
Faderl, S.
Koller, C.
Estrov, Z.
Garcia-Manero, G.
Verstovsek, S.
Browning, M.
Lerner, S.
Keating, M.
BLOOD, 2007, 110 (11) : 194A - 194A
[4] Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL.
Wierda, WG
OBrien, S
Ferrajoli, A
Faderl, S
Koller, C
Giles, F
Cortes, J
Thomas, D
Ravandi, F
Garcia-Manero, G
Andreeff, M
Lerner, S
Kantarjian, H
Keating, M
BLOOD, 2005, 106 (11) : 213A - 213A
[5] Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Badoux, Xavier C.
Keating, Michael J.
Wang, Xuemei
O'Brien, Susan M.
Ferrajoli, Alessandra
Faderl, Stefan
Burger, Jan
Koller, Charles
Lerner, Susan
Kantarjian, Hagop
Wierda, William G.
BLOOD, 2011, 117 (11) : 3016 - 3024
[6] Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia
Badoux, Xavier C.
Keating, Michael
O'Brien, Susan
Kadia, Tapan
Ferrajoli, Alessandra
Faderl, Stefan
Koller, Charles
Garcia-Manero, Guillermo
Burger, Jan A.
Wierda, William G.
BLOOD, 2009, 114 (22) : 1332 - 1333
[7] Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL)
Montillo, Marco
Miqueleiz, Sara
Tedeschi, Alessandra
Ricci, Francesca
Vismara, Eleonora
Ciapanna, Denis
Petrizzi, Valeria Belsito
Crugnola, Monica
Spriano, Mauro
Uziel, Lilj
De Blasio, Angelo
Spedini, Pierangelo
Morra, Enrica
BLOOD, 2007, 110 (11) : 922A - 922A
[8] Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia
Parikh, Sameer A.
Keating, Michael
O'Brien, Susan
Ferrajoli, Alessandra
Faderl, Stefan
Koller, Charles
Estrov, Zeev
Lerner, Susan
Wierda, William G.
BLOOD, 2009, 114 (22) : 91 - 92
[9] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
O'Brien, S.
Byrd, J. C.
Kipps, T. J.
Forero-Torres, A.
Flinn, I. W.
Wynne, D. I.
Molina, A.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
[10] Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).
Tedeschi, A
Montillo, M
Miqueleiz, S
Draisci, M
Ricci, F
Scarpati, B
Mura, ME
Crugnola, M
Morra, E
BLOOD, 2005, 106 (11) : 341B - 341B

← 1 2 3 4 5 →